Patent · US Active

Treatment for methamphetamine cardiovascular disease

US11883426B2 · kind B2 · utility

0Cited by

0References

16Claims

0Family size

Assignee

BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE · US

Inventors

Christopher KEVIL · Shreveport, US
Gopi K. Kolluru · Shreveport, US

Key dates

Filing date	Aug 9, 2021
Grant date	Jan 30, 2024
Priority date	—
Expiry date	Aug 9, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y404/01001
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, allicin, sugammadex, sulfanilamide, disulfiram, sulfonamide, sulfonates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.